scholarly journals The Landscape of Severe Combined Immunodeficiency Newborn Screening in the United States in 2020: A Review of Screening Methodologies and Targets, Communication Pathways, and Long-Term Follow-Up Practices

2020 ◽  
Vol 11 ◽  
Author(s):  
Ruthanne Sheller ◽  
Jelili Ojodu ◽  
Emma Griffin ◽  
Sari Edelman ◽  
Careema Yusuf ◽  
...  
2021 ◽  
Vol 2 (1) ◽  
pp. 218-225
Author(s):  
Terrah Foster Akard ◽  
Samantha Burley ◽  
Maggie C. Root ◽  
Mary S. Dietrich ◽  
Brittany Cowfer ◽  
...  

2009 ◽  
Vol 53 (7) ◽  
pp. 1295-1301 ◽  
Author(s):  
Daniel C. Bowers ◽  
Soumya Adhikari ◽  
Yasmin M. El-Khashab ◽  
Lynn Gargan ◽  
Kevin C. Oeffinger

JAMA ◽  
2014 ◽  
Vol 312 (7) ◽  
pp. 729 ◽  
Author(s):  
Antonia Kwan ◽  
Roshini S. Abraham ◽  
Robert Currier ◽  
Amy Brower ◽  
Karen Andruszewski ◽  
...  

PEDIATRICS ◽  
1988 ◽  
Vol 82 (2) ◽  
pp. 276-277
Author(s):  
STEVEN M. DONN

The number of centers providing extracorporeal membrane oxygenation (ECMO) therapy to newborns with intractable respiratory failure has grown dramatically. The ECMO registry now includes 37 institutions in the United States,1 and there may be additional centers offering ECMO but not participating in the registry. To date, more than 1,400 patients have been treated with ECMO with a survival rate exceeding 80%. Widespread acceptance of ECMO therapy has been accomplished despite a paucity of controlled clinical trials2 and without the benefit of long-term follow-up of survivors. Initial fervor about neonatal ECMO has stemmed from the excellent survival statistics cited by most of the earlier investigators.2-4


Sign in / Sign up

Export Citation Format

Share Document